Keeping prior anticoagulation treatment in the acute phase of ischaemic stroke: the REKOALA study
Authors:
Open Access
- 5 April 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4086-4094
Abstract
Introduction: A consensus on the management of anticoagulated patients in the acute phase of ischaemic stroke has not yet been established. We aimed to evaluate clinical outcomes in such patients based on the continuation or discontinuation of anticoagulation. Methods: Retrospective study of patients with acute ischaemic stroke and cardioembolic source receiving anticoagulant therapy is done. Patients were classified based on the continuation or discontinuation of anticoagulation at admission. Clinical outcomes, haemorrhagic and ischaemic events were assessed. Multivariate logistic regression analysis, propensity score matching (PSM) analysis and a sub-analysis of patients with severe ischaemic stroke at admission (NIHSS score ≥ 15) were performed. Results: Anticoagulation was continued in 147 (78.8%) of 186 patients. Patients continuing anticoagulant had lower NIHSS (median 5 vs 18, p < 0.001). There were no differences in haemorrhagic or ischaemic events. In the multivariate analysis, good functional outcome at discharge was higher in the continuation group, OR (CI95%) 3.77 (1.2–11.2). PSM analysis adjusted for potential confounders such as NIHSS had higher rates of good functional outcomes at discharge (80% vs 36%, p = 0.004) and at 90 days (76% vs 44%, p = 0.042) in the continuation group. Patients with severe stroke in this group had lower 90-day mortality (34.6% vs 62.5%, p = 0.045) and higher rates of good clinical outcome at discharge (33.3% vs 8.3%, p = 0.032). No differences were observed in 90-day haemorrhagic or ischaemic events. Conclusion: Continuation of anticoagulation in patients with acute ischaemic stroke and cardioembolic source did not increase the risk of intracranial haemorrhage and may be associated with better functional outcomes.Keywords
Funding Information
- RICORS (RD21/0006/0012)
- Universidad Autónoma de Madrid
This publication has 24 references indexed in Scilit:
- Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulationEuropean Heart Journal, 2023
- Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority StudyCirculation, 2022
- Early versus late start of direct oral anticoagulants after acute ischaemic stroke linked to atrial fibrillation: an observational study and individual patient data pooled analysisJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC studyJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial FibrillationAnnals of Neurology, 2020
- Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registryOpen Heart, 2019
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillationEuropean Heart Journal, 2018
- Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) StudyJournal of the American Heart Association, 2017
- Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial FibrillationStroke, 2015
- Hemorrhagic Transformation Within 36 Hours of a Cerebral InfarctStroke, 1999